BACKGROUND: Children with comorbidities or danger signs are often excluded from trials evaluating pneumonia treatment. METHODS: We sought to investigate whether the percentage of children with chest-indrawing pneumonia cured at Day 14 was lower among those with HIV infection or exposure, malaria, moderate or severe acute malnutrition, or anemia enrolled in a prospective observational cohort study than among children without these comorbidities enrolled in a concurrent prospective randomized controlled trial evaluating duration of amoxicillin treatment in Lilongwe, Malawi. RESULTS: Children with chest-indrawing pneumonia and comorbidities but without danger signs did not have statistically significant higher treatment failure rates by Day 6 than those in the chest-indrawing pneumonia clinical trial. However, children with chest-indrawing pneumonia and HIV infection or exposure, malaria, or moderate or severe acute malnutrition had higher rates of not being clinically cured at Day 14 when compared to children without these comorbidities (adjusted differences ranging from 7.7% to 17.0%). Furthermore, among children without danger signs at enrollment, but with HIV infection or HIV exposure or moderate or severe acute malnutrition, 12.5% and 15.6% respectively were not clinically cured at Day 14 even though they were without treatment failure by Day 6. CONCLUSIONS: More intensive follow-up of children with chest-indrawing pneumonia and comorbidities who do not have danger signs may be beneficial.
BACKGROUND: Children with comorbidities or danger signs are often excluded from trials evaluating pneumonia treatment. METHODS: We sought to investigate whether the percentage of children with chest-indrawing pneumonia cured at Day 14 was lower among those with HIV infection or exposure, malaria, moderate or severe acute malnutrition, or anemia enrolled in a prospective observational cohort study than among children without these comorbidities enrolled in a concurrent prospective randomized controlled trial evaluating duration of amoxicillin treatment in Lilongwe, Malawi. RESULTS: Children with chest-indrawing pneumonia and comorbidities but without danger signs did not have statistically significant higher treatment failure rates by Day 6 than those in the chest-indrawing pneumonia clinical trial. However, children with chest-indrawing pneumonia and HIV infection or exposure, malaria, or moderate or severe acute malnutrition had higher rates of not being clinically cured at Day 14 when compared to children without these comorbidities (adjusted differences ranging from 7.7% to 17.0%). Furthermore, among children without danger signs at enrollment, but with HIV infection or HIV exposure or moderate or severe acute malnutrition, 12.5% and 15.6% respectively were not clinically cured at Day 14 even though they were without treatment failure by Day 6. CONCLUSIONS: More intensive follow-up of children with chest-indrawing pneumonia and comorbidities who do not have danger signs may be beneficial.
Authors: Marzia Lazzerini; Nadine Seward; Norman Lufesi; Rosina Banda; Sophie Sinyeka; Gibson Masache; Bejoy Nambiar; Charles Makwenda; Anthony Costello; Eric D McCollum; Tim Colbourn Journal: Lancet Glob Health Date: 2016-01 Impact factor: 26.763
Authors: Eric D McCollum; Bejoy Nambiar; Rashid Deula; Beatiwel Zadutsa; Austin Bondo; Carina King; James Beard; Harry Liyaya; Limangeni Mankhambo; Marzia Lazzerini; Charles Makwenda; Gibson Masache; Naor Bar-Zeev; Peter N Kazembe; Charles Mwansambo; Norman Lufesi; Anthony Costello; Ben Armstrong; Tim Colbourn Journal: PLoS One Date: 2017-01-04 Impact factor: 3.240
Authors: Amy-Sarah Ginsburg; Tisungane Mvalo; Evangelyn Nkwopara; Eric D McCollum; Melda Phiri; Robert Schmicker; Jun Hwang; Chifundo B Ndamala; Ajib Phiri; Norman Lufesi; Susanne May Journal: N Engl J Med Date: 2020-07-02 Impact factor: 91.245
Authors: Amy Sarah Ginsburg; Susanne May; Evangelyn Nkwopara; Gwen Ambler; Eric D McCollum; Tisungane Mvalo; Ajib Phiri; Norman Lufesi Journal: JMIR Res Protoc Date: 2019-07-29
Authors: Li Liu; Shefali Oza; Daniel Hogan; Jamie Perin; Igor Rudan; Joy E Lawn; Simon Cousens; Colin Mathers; Robert E Black Journal: Lancet Date: 2014-09-30 Impact factor: 79.321
Authors: Nicholas Fancourt; Maria Deloria Knoll; Henry C Baggett; W Abdullah Brooks; Daniel R Feikin; Laura L Hammitt; Stephen R C Howie; Karen L Kotloff; Orin S Levine; Shabir A Madhi; David R Murdoch; J Anthony G Scott; Donald M Thea; Juliet O Awori; Breanna Barger-Kamate; James Chipeta; Andrea N DeLuca; Mahamadou Diallo; Amanda J Driscoll; Bernard E Ebruke; Melissa M Higdon; Yasmin Jahan; Ruth A Karron; Nasreen Mahomed; David P Moore; Kamrun Nahar; Sathapana Naorat; Micah Silaba Ominde; Daniel E Park; Christine Prosperi; Somwe Wa Somwe; Somsak Thamthitiwat; Syed M A Zaman; Scott L Zeger; Katherine L O'Brien Journal: Clin Infect Dis Date: 2017-06-15 Impact factor: 9.079
Authors: Mohammod Jobayer Chisti; Chowdhury Ali Kawser; Abu Sayem Mirza Md Hasibur Rahman; Abu Sadat Mohammad Sayeem Bin Shahid; Farzana Afroze; K M Shahunja; Lubaba Shahrin; Monira Sarmin; Sharika Nuzhat; Ahmed Ehsanur Rahman; Tahmina Alam; Irin Parvin; M S T Mahmuda Ackhter; Gazi Md Salahuddin Mamun; Shamsun Nahar Shaima; Abu Syed Golam Faruque; Tahmeed Ahmed Journal: Sci Rep Date: 2022-06-24 Impact factor: 4.996